NCT00079950暂停2 期
Efficacy and Safety Evaluation of Pegamotecan (PEG-camptothecin) in Advanced or Metastatic Soft Tissue Sarcoma
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 暂停
- 试验地点
- 4
研究概览
简要总结
The purpose of this study is to evaluate the safety and efficacy of Pegamotecan (Peg-Camptothecin) in patients with Advanced or Metastatic Soft Tissue sarcoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed diagnosis of soft tissue sarcoma with measurable disease.
- •Target tumors outside prior radiation field(s).
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-
- •Adequate hematologic profile, as determined by hemoglobin, platelet, and neutrophil count.
- •Adequate renal function
- •Adequate liver function
- •No history of hemorrhagic cystitis or evidence of microscopic hematuria
- •Capable of understanding the protocol requirements and risks and providing written informed consent.
- •Either 0 or 1 prior chemotherapy regimens
排除标准
- •Subject has a diagnosis of gastrointestinal stromal tumors.
- •Concurrent serious medical illness unrelated to tumor within the past 6 months.
- •Known chronic infectious disease, such as AIDS or hepatitis.
- •Positive screening pregnancy test or is breast-feeding.
- •A female or male subject of reproductive capacity unwilling to use methods appropriate to prevent pregnancy during the course of this study.
- •Receiving concurrent chemotherapy, radiotherapy, or surgery, or has received wide field radiation within the previous 4 weeks.
- •History of another active malignancy (except non-melanoma skin cancer and carcinoma in situ of the cervix), unless in complete remission and off all therapy for that disease for the last 2 years.
- •Known or clinically suspected brain metastases.
- •Received more than one prior treatment regimen (excluding adjuvant or neoadjuvant therapy) for soft tissue sarcoma.
- •Received any investigational drug within the last 30 days.
- •Not fully recovered from any prior surgery (at least 4 weeks recovery period for major surgery), and from any reversible side effects related to the administration of cytotoxic chemotherapy or radiation therapy.
- •Received a prior camptothecin analog (e.g., topotecan, irinotecan).
研究者
研究点 (4)
Loading locations...
相似试验
终止
2 期
Efficacy of Pegamotecan (PEG-Camptothecin) in Localized or Metastatic Cancer of the Stomach or Gastroesophageal JunctionCancer of StomachGastroesophageal CancerNCT00080002Enzon Pharmaceuticals, Inc.
已完成
不适用
Safety and Effectiveness Assessment of PeGagen® (Pegfilgrastim) in the Prevention of Chemotherapy-induced FNChemotherapy-induced NeutropeniaNCT04460079Cinnagen654
已完成
1 期
Effect of a Pomegranate Extract on Cardiovascular Risk Markers in Overweight Healthy SubjectsOverweightNCT02061098National Research Council, Spain50
招募中
2 期
A Phase II Clinical Study of Epigallocatechin-3-gallate in Patients With Esophageal Squamous CancerDysphagia, EsophagealEpigallocatechin GallateEsophageal CancerNCT06398405Shandong Cancer Hospital and Institute72
已完成
2 期
A Study of Pegcetacoplan for Patients With Transplant-associated Thrombotic Microangiopathy After Hematopoietic Stem Cell TransplantationTransplant-Associated Thrombotic MicroangiopathyNCT05148299Swedish Orphan Biovitrum12